Talk:Ofranergene obadenovec

Developer
This source states clearly that the drug is being developed by "Dana-Farber Cancer Institute; Massachusetts General Hospital; VBL Therapeutics". Why is only the last mentioned in the article? You should mention all or none, I think. Justlettersandnumbers (talk) 21:42, 23 February 2017 (UTC)
 * The drug itself was developed by VBL. Dana-Farber (which is associated with Mass Gen) is being used to host clinical trials and further testing of the drug. Natureium (talk) 15:26, 24 February 2017 (UTC)
 * But that isn't what the source says, is it? Justlettersandnumbers (talk) 15:44, 24 February 2017 (UTC)
 * From the first sentence: "VBL Therapeutics (also known as Vascular Biogenics) is developing ofranergene obadenovec, an intravenously administered dual-action, anti-angiogenic and vascular disrupting agent (VDA), for the treatment of solid tumours." and the table further down the page: "VBL Therapeutics,	Owner,	Israel; Dana-Farber Cancer Institute,	Collaborator,	USA; Massachusetts General Hospital,	Collaborator,	USA" Natureium (talk) 15:50, 24 February 2017 (UTC)
 * yep, the drug is owned by VBL and is being developed by them at various sites. adis lists clinical trial sites. Dana Farber is one of them.  Jytdog (talk) 19:56, 29 August 2017 (UTC)